PriceTargets.com logo

Royalty Pharma - RPRX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $41.67
  • Forecasted Upside: 67.20%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$24.92 As of 12/20/2024 06:51 PM ET
▲ +0.64 (2.64%)

This chart shows the closing price for RPRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Royalty Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RPRX

Analyst Price Target is $41.67
▲ +67.20% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Royalty Pharma in the last 3 months. The average price target is $41.67, with a high forecast of $51.00 and a low forecast of $28.00. The average price target represents a 67.20% upside from the last price of $24.92.

This chart shows the closing price for RPRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 polled investment analysts is to moderate buy stock in Royalty Pharma. This rating has held steady since May 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/25/2024CitigroupLower TargetBuy ➝ Buy$60.00 ➝ $40.00
8/14/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$50.00 ➝ $51.00
7/11/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$48.00 ➝ $51.00
6/3/2024UBS GroupDowngradeBuy ➝ Neutral$28.00
4/12/2024Bank of AmericaLower TargetBuy ➝ Buy$40.00 ➝ $38.00
2/20/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$45.00 ➝ $42.00
2/20/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$56.00 ➝ $50.00
11/9/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$54.00 ➝ $57.00
10/11/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$53.00 ➝ $54.00
8/9/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$52.00 ➝ $53.00
4/10/2023Morgan StanleyBoost TargetOverweight$48.00 ➝ $50.00
4/6/2023Tigress FinancialBoost TargetBuy$57.00 ➝ $60.00
2/16/2023UBS GroupLower TargetBuy$51.00 ➝ $48.00
12/6/2022Morgan StanleyLower TargetOverweight$54.00 ➝ $51.00
11/9/2022Morgan StanleyBoost TargetOverweight$51.00 ➝ $54.00
10/18/2022JPMorgan Chase & Co.Boost TargetOverweight$50.00 ➝ $52.00
8/8/2022Morgan StanleyBoost TargetOverweight$48.00 ➝ $51.00
7/28/2022CitigroupBoost Target$50.00 ➝ $60.00
7/14/2022Tigress FinancialBoost TargetBuy$52.00 ➝ $57.00
6/13/2022UBS GroupInitiated CoverageBuy$47.00
6/3/2022UBS GroupBoost Target$51.00
5/13/2022ScotiabankInitiated CoverageOutperform$53.00
4/27/2022The Goldman Sachs GroupInitiated CoverageBuy$56.00
4/14/2022JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$50.00
4/6/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$46.00 ➝ $48.00
10/29/2021CitigroupUpgradeNeutral ➝ Buy$50.00
8/16/2021Morgan StanleyLower TargetEqual Weight$51.00 ➝ $46.00
7/30/2021Tigress FinancialInitiated CoverageBuy$50.00
11/9/2020UBS GroupUpgradeNeutral ➝ Buy$52.00 ➝ $51.00
7/14/2020Evercore ISIInitiated CoverageHold
7/13/2020Bank of AmericaInitiated CoverageBuy$55.00
7/13/2020CitigroupInitiated CoverageNeutral$50.00
7/13/2020Morgan StanleyInitiated CoverageEqual Weight$51.00
7/13/2020SunTrust BanksInitiated CoverageBuy$56.00
7/13/2020UBS GroupInitiated CoverageNeutral$52.00
7/13/2020JPMorgan Chase & Co.Initiated CoverageNeutral$50.00
7/13/2020CowenInitiated CoverageOutperform$55.00
7/12/2020The Goldman Sachs GroupInitiated CoverageNeutral$47.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.43 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 16 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 22 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 15 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 11 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 19 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 21 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 23 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 29 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 29 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Royalty Pharma logo
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Read More

Today's Range

Now: $24.92
Low: $24.32
High: $25.00

50 Day Range

MA: $26.43
Low: $24.28
High: $28.22

52 Week Range

Now: $24.92
Low: $24.05
High: $31.66

Volume

7,574,639 shs

Average Volume

2,691,117 shs

Market Capitalization

$14.68 billion

P/E Ratio

12.91

Dividend Yield

3.43%

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Royalty Pharma?

The following sell-side analysts have issued stock ratings on Royalty Pharma in the last twelve months: Bank of America Co., Citigroup Inc., JPMorgan Chase & Co., Morgan Stanley, StockNews.com, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for RPRX.

What is the current price target for Royalty Pharma?

0 Wall Street analysts have set twelve-month price targets for Royalty Pharma in the last year. Their average twelve-month price target is $41.67, suggesting a possible upside of 67.2%. The Goldman Sachs Group, Inc. has the highest price target set, predicting RPRX will reach $51.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $28.00 for Royalty Pharma in the next year.
View the latest price targets for RPRX.

What is the current consensus analyst rating for Royalty Pharma?

Royalty Pharma currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RPRX.

What other companies compete with Royalty Pharma?

Other companies that are similar to Royalty Pharma include Jazz Pharmaceuticals, Corcept Therapeutics, Perrigo, Supernus Pharmaceuticals and Pacira BioSciences. Learn More about companies similar to Royalty Pharma.

How do I contact Royalty Pharma's investor relations team?

Royalty Pharma's physical mailing address is 110 E 59th Street, New York NY, 10022. The biopharmaceutical company's listed phone number is 212-883-0200 and its investor relations email address is [email protected]. The official website for Royalty Pharma is www.royaltypharma.com. Learn More about contacing Royalty Pharma investor relations.